Investigating how Pellino1 affects the skin's ability to fight viruses
Official title: Pellino1 as a regulator of antiviral immunity in the epidermis
Funded at Temple Univ of the Commonwealth · NIH-11058681 · Data updated 2026-11-12
This study is looking at how a protein called Pellino1 helps the skin fight off viral infections, especially for people with atopic dermatitis, a skin condition that can make it harder for the body to respond to viruses like herpes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | November 15, 2024 |
| Project end | October 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $384,363 |
| NIH project number | 1R01AI182537-01A1 |
| Project ID | NIH-11058681 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults with atopic dermatitis or other conditions that affect skin barrier function and immune response.
✕Less likely to help
Patients without skin conditions or those who do not have compromised immune systems may not benefit from this research.
What this research studies
This research focuses on understanding the role of Pellino1, a protein involved in immune signaling, in the skin's response to viral infections, particularly herpes simplex viruses. The study aims to explore how Pellino1 influences antiviral immunity in individuals with atopic dermatitis, a common skin condition that can weaken the immune response. By using mouse models, researchers will examine the effects of Pellino1 on the severity of skin lesions and viral spread, which could lead to new treatment strategies for patients with compromised skin barriers. The findings may help identify ways to enhance the skin's antiviral defenses.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients with skin conditions that compromise their immune response to viral infections.
How similar studies have gone: Previous research has shown that targeting immune signaling pathways can improve antiviral responses, suggesting potential success for this approach.
Where this research is happening
-
Temple Univ of the Commonwealth
Philadelphia, United States Active
Researchers
- Principal investigator: Jensen, Liselotte E — Temple Univ of the Commonwealth
- Study coordinator: Jensen, Liselotte E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.